MALVERN, Pa. - Neuronetics , Inc. (NASDAQ: NASDAQ:STIM), a medical technology company, has announced new clinical research findings in the field of neuromodulation. Published in Brain Stimulation, the study indicates that early symptom improvement during transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) does not necessarily predict the final outcome.
The research, drawn from the NeuroStar Outcomes Registry, analyzed the treatment progress of 7,215 MDD patients undergoing NeuroStar TMS Therapy. It found that patients who do not show early improvement still have a significant chance of experiencing symptom reduction by the end of the full 36-session treatment course.
Cory Anderson, Senior Vice President of Research & Development and Clinical at Neuronetics, emphasized the study's implications for healthcare providers and patients, suggesting that completing the prescribed TMS regimen is crucial for achieving the best results. The findings challenge the notion that lack of early improvement is indicative of final non-response, a view that has influenced clinical decisions and insurance practices.
Dr. Harold Sackeim, Professor in Psychiatry and Radiology at Columbia University and the lead investigator of the study, highlighted that prematurely discontinuing TMS treatment could deprive patients of a beneficial therapy. The analysis showed that even at 20 sessions, predictions of non-response were only 63% accurate.
The study builds on previous research from October 2023, which established a strong correlation between the number of completed treatment sessions and improved clinical outcomes for depression. Neuronetics utilizes data from its proprietary TrakStar database to support clinical decisions and optimize TMS therapy for MDD.
Neuronetics' NeuroStar Advanced Therapy is an FDA-cleared, non-invasive treatment for depression and other mental health conditions. The company's commitment to mental health innovation is reflected in its efforts to provide clinicians with data to effectively prescribe TMS therapy.
The information presented is based on a press release statement from Neuronetics, Inc.
InvestingPro Insights
Neuronetics, Inc. (NASDAQ: STIM) has been making strides in the medical technology sector, particularly with its latest clinical research in neuromodulation. While the company is focused on advancing treatment for major depressive disorder, it's important for investors to consider the financial health and market performance of the company as well. The following insights from InvestingPro provide a snapshot of Neuronetics' current financial metrics and stock performance:
- The company's market capitalization stands at $131.82 million, reflecting its valuation in the market as of the last trading session.
- Neuronetics has a negative P/E ratio of -4.19, indicating that it currently does not generate earnings to cover its share price. This is consistent with the InvestingPro Tips that analysts do not expect the company to be profitable this year.
- Despite the challenges in profitability, the company has experienced a strong return over the last three months, with a price total return of 20.64%, and an even more impressive surge over the last six months at 245.83%.
Investors should note that Neuronetics operates with a moderate level of debt and its liquid assets exceed short-term obligations, which may provide some financial stability. However, the company has been quickly burning through cash, and two analysts have revised their earnings downwards for the upcoming period. These factors, combined with the stock's notable volatility, should be carefully weighed when considering an investment in Neuronetics.
For those looking to delve deeper into Neuronetics' financials and stock performance, additional InvestingPro Tips are available, providing a comprehensive analysis of the company. There are 11 additional tips listed on InvestingPro, which can be accessed at: https://www.investing.com/pro/STIM. To enhance your investment research experience, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.